Alzheimer’s disease is the most common cause of dementia, affecting over 6 million people in the US.¹ Quest AD-Detect^® is a portfolio of blood-based offerings that can help uncover a broader view of your patients’ Alzheimer’s disease risk.

 

Combining clinical cognitive assessments and insights from blood-based biomarker testing allows you to balance clinical evaluations with objective data, guiding next steps along the care pathway.

ANAlyzeR is a fixed panel of 25 analytes that gives a full-picture view (whether ANA is positive or negative) to support differential diagnosis, especially for patients with more than 1 autoimmune condition.

 

 

Elevated PSA levels are not specific to prostate cancer and can result from benign conditions such as prostatitis, inflammation, benign prostatic hyperplasia (BPH), or indolent cancers.

 

IsoPSA helps clarify if elevated PSA came from cancer cells by analyzing the structure of PSA proteins.

InSure ONE is the only FIT that is performed using toilet water collected from a single bowel movement. There is no stool collection or handling required, and there are no dietary or medicinal restrictions. This helps increase the likelihood your patient will actually complete the test, and may lead to an improvement in quality measures such as HEDIS.

 

The Cardiometabolic Disease Assessment (CMDA) Panel from Quest provides a comprehensive approach to identifying and quantifying the presence of cardiometabolic disease across multiple interrelated organ systems, for deeper insights into cardiometabolic disease presence and progression.

 

This includes metabolic disease, cardiovascular disease, common endocrine disorders, chronic kidney disease, and non-alcoholic fatty liver disease, also known as metabolic dysfunction-associated steatotic liver disease (MASLD).

When it comes to infectious diseases like hepatitis, HIV, or tuberculosis (TB), screening helps prevent chronic infections from becoming major health issues. Knowing which patients to screen is a crucial step toward stopping disease spread and preventing serious illness. Understanding a patient's status helps connect them to care more quickly and improve outcomes.

Primary aldosteronism (PA) is a condition that can lead to serious health complications if patients aren’t screened and diagnosed. 2025 Endocrine Society guidelines now suggested PA screening for all patients with hypertension. Quest's streamlined reflex testing solution helps identify more patients with PA.